Tag #Relocalisation

What are the key factors contributing to Europe's pharmaceutical supply chain vulnerabilities, and what are the immediate consequences?

Europe's efforts to regain pharmaceutical sovereignty are slow, with many medications still in short supply due to reliance on distant countries for raw materials and production. This model, prioritizing low costs, led to 80% of essential active ingredients originating from India or China, a significant increase from 20% two decades ago.